Leap Therapeutics Inc. (NASDAQ:LPTX) does about 702.00K shares in volume on a normal day but saw 4877743 shares change hands in Friday trading. The company now has a market cap of 53.41M USD. Its current market price is $0.72, marking an increase of 33.44% compared to the previous close of $0.54. The 52 week high reached by this stock is $2.98 whilst the lowest price level in 52 weeks is $0.40. The script in recent trading has seen the stock touch a high of $0.7878 and a low of $0.5522.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Leap Therapeutics Inc. (LPTX) has a 20-day trading average at $0.4980 and the current price is -75.87% off the 52-week high compared with 79.77% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.5321 and its 200-day simple moving average is $1.0159. If we look at the stock’s price movements over the week, volatility stands at 22.62%, which decreases to 13.39% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 68.84 to suggest the stock is neutral.
The consensus objective for the share price is $3.60, suggesting that the stock has a potential upside of 80.0% over the period. The median price target is 76.0% away from the current levels at $3.00.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 04, 2021 when Mizuho initiated the stock to “Buy” and issued a price target of $6. Piper Sandler initiated its price target at $6.
The current price level is 48.68%, 34.90%, and -29.63% away from its SMA20, SMA50, and SMA200 respectively, with the LPTX price moving below the 50-day SMA on January 20. Leap Therapeutics Inc. (LPTX) stock is up 35.14% over the week and 57.73% over the past month. Its price is 59.80% year-to-date and -74.77% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.15 below consensus estimates by -$0.05. The company’s next earnings report is expected on 05/12/2023, with forecasts estimating quarterly EPS at -$0.12 and -$0.48 for whole year. LPTX’s earnings per share are forecast to shrink by -2.10% this year and -2.10% over next year.
Its 12-month price target is $3.00. To reach the target analysts have set, the stock logically needs to grow 80.0 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $2.50, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $6.00.
Outstanding shares total 113.24M with insiders holding 9.26% of the shares and institutional holders owning 45.19% of the company’s common stock. The company has a return on investment of -38.40% and return on equity of -59.20%. The beta has a value of 0.60. Price to book ratio is 1.16 and price to sales ratio is 133.52.
Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which added 1374.0 shares to end up with 851,630 shares worth $0.38 million.
